Coloplast A/S
CLPBYOTCHealthcare● Active
$5.94
$-0.02(-0.34%)
Market Cap$13.4B
P/E Ratio—
52W High$10.03
52W Low$5.88
Coloplast A/S (CLPBY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLPBY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
$0.10
Est. $0.09 · +11.1%
Revenue
$1.11B
Est. $1.11B · +0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
CLPBY reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | $0.10 | — | — | — | $1.14B | — |
| ▲ Q2 FY2026 | May 12, 2026 | $0.09 | $0.10 | +11.1% | $1.11B | $1.11B | +0.2% |
| ▲ Q1 FY2026 | Feb 6, 2026 | $0.09 | $0.10 | +11.1% | $1.11B | $1.12B | -0.6% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.09 | $0.07 | -26.0% | $1.09B | $1.10B | -1.1% |
| ▲ Q3 FY2025 | Aug 19, 2025 | $0.02 | $0.06 | +235.2% | $1.10B | $1.09B | +0.7% |
| ▲ Q2 FY2025 | May 6, 2025 | $0.01 | $0.06 | +333.5% | $1.02B | $1.08B | -5.5% |
| ▼ Q1 FY2025 | Feb 4, 2025 | $0.08 | $0.07 | -12.5% | $0.97B | $0.98B | -0.5% |
| ▼ Q4 FY2024 | Nov 5, 2024 | $0.09 | $0.08 | -6.6% | $1.02B | $1.02B | +0.4% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
$0.10
EPS Est.
$0.09
EPS Surpr.
+11.1%
Revenue
$1.11B
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
$0.10
EPS Est.
$0.09
EPS Surpr.
+11.1%
Revenue
$1.11B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.07
EPS Est.
$0.09
EPS Surpr.
-26.0%
Revenue
$1.09B
Q3 FY2025
Aug 19, 2025Beat
EPS Actual
$0.06
EPS Est.
$0.02
EPS Surpr.
+235.2%
Revenue
$1.10B
Q2 FY2025
May 6, 2025Beat
EPS Actual
$0.06
EPS Est.
$0.01
EPS Surpr.
+333.5%
Revenue
$1.02B
Q1 FY2025
Feb 4, 2025Miss
EPS Actual
$0.07
EPS Est.
$0.08
EPS Surpr.
-12.5%
Revenue
$0.97B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
$0.08
EPS Est.
$0.09
EPS Surpr.
-6.6%
Revenue
$1.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $1.30 | $1.33 | $1.35 | 1 |
| Q3 FY2026 | $0.62 | $0.63 | $0.64 | 1 |
| Q2 FY2026 | $0.62 | $0.63 | $0.64 | 1 |
| Q1 FY2026 | $0.59 | $0.60 | $0.61 | 1 |
| Q4 FY2025 | $0.60 | $0.62 | $0.63 | 1 |
| Q3 FY2025 | $0.59 | $0.60 | $0.61 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $7.4B | $7.6B | $7.6B | 7 |
| Q3 FY2026 | $7.3B | $7.5B | $7.6B | 8 |
| Q2 FY2026 | $7.3B | $7.4B | $7.5B | 8 |
| Q1 FY2026 | $7.1B | $7.2B | $7.2B | 6 |
| Q4 FY2025 | $7.1B | $7.1B | $7.2B | 9 |
| Q3 FY2025 | $6.9B | $7.0B | $7.1B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +11.1% | $6.33 | $6.43 | +1.58% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +11.1% | $8.40 | $7.81 | -7.02% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -26.0% | $9.05 | $9.48 | +4.75% |
| ▲ Q3 FY2025 | Aug 19, 2025 | +235.2% | $9.67 | $9.46 | -2.17% |
| ▲ Q2 FY2025 | May 6, 2025 | +333.5% | $10.65 | $9.90 | -7.04% |
| ▼ Q1 FY2025 | Feb 4, 2025 | -12.5% | $11.29 | $11.13 | -1.42% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -6.6% | $12.84 | $12.98 | +1.09% |
| ▼ Q3 FY2024 | Aug 20, 2024 | -8.7% | $14.03 | $13.31 | -5.13% |
Q2 FY2026+1.58%
Report Date
May 12, 2026
EPS Beat/Miss
+11.1%
Price Before
$6.33
Price After
$6.43
Q1 FY2026-7.02%
Report Date
Feb 6, 2026
EPS Beat/Miss
+11.1%
Price Before
$8.40
Price After
$7.81
Q4 FY2025+4.75%
Report Date
Nov 4, 2025
EPS Beat/Miss
-26.0%
Price Before
$9.05
Price After
$9.48
Q3 FY2025-2.17%
Report Date
Aug 19, 2025
EPS Beat/Miss
+235.2%
Price Before
$9.67
Price After
$9.46
Q2 FY2025-7.04%
Report Date
May 6, 2025
EPS Beat/Miss
+333.5%
Price Before
$10.65
Price After
$9.90
Q1 FY2025-1.42%
Report Date
Feb 4, 2025
EPS Beat/Miss
-12.5%
Price Before
$11.29
Price After
$11.13
Q4 FY2024+1.09%
Report Date
Nov 5, 2024
EPS Beat/Miss
-6.6%
Price Before
$12.84
Price After
$12.98
Q3 FY2024-5.13%
Report Date
Aug 20, 2024
EPS Beat/Miss
-8.7%
Price Before
$14.03
Price After
$13.31
Avg Beat Reaction-3.66%
Avg Miss Reaction-0.18%
Beat Rate4 / 8 quarters
Largest Move-7.04% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLPBY ends December
Coloplast A/S (CLPBY) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $0.10 — beating the analyst consensus of $0.09 by +11.1%. CLPBY has beaten EPS estimates for 2 consecutive quarters. The next CLPBY earnings date is expected around September 1, 2026.
Each quarter, investors track CLPBY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLPBY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLPBY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLPBY earnings · 5 questionsColoplast A/S's next earnings report is expected around September 1, 2026. CLPBY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLPBY historically reports after market close (AMC).
CLPBY earnings datewhen is CLPBY earningsCLPBY next earnings datewhen does CLPBY report earningsCLPBY earnings calendar
▸ Source: FMP · Coloplast A/S SEC filings · US GAAP · Coloplast A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026